Miconazole Nitrate 2% Topical
For external use only. Avoid introduction into the eyes. Lactation: not known whether distributed into milk; use caution
Skin and nail infections due to dermatophytes, yeasts and other fungi such as:, Tinea capitis, corporis, manuum, pedis, barbae, cruris, unguium or onychomycosis, Pityriasis versicolor, candidiasis of skin and nails, stomatitis angularis, otitis externa, mycoses secondarily infected with bacteria.
History of sensitivity reactions to Miconazole or any of the components of the preparation.
N/A
Irritation,BurningmMaceration,Allergic contact dermatitis Irritation, burning, maceration, allergic contact dermatitis (all rare)
Miconazole inhibits ergosterol synthesis thus damaging fungal cell wall membrane and increases its permeability, allowing leakage of nutrients.
May increase anticoagulant effect of warfarin. May increase or prolong the effect of the following drugs: Oral hypoglycaemics (e.g. sulfonylureas), phenytoin, HIV protease inhibitors (e.g. saquinavir), antineoplastic agents (e.g. vinca alkaloids, busulfan, docetaxel), Ca channel blockers (e.g. dihydropyridines, verapamil), immunosuppressive agents (e.g. ciclosporin, tacrolimus, sirolimus), carbamazepine, cilostazol, buspirone, disopyramide, alfentanil, sildenafil, alprazolam, brotizolam, midazolam IV, rifabutin, methylprednisolone, trimetrexate, ebastine and reboxetine. Potentially Fatal: Increased risk of cardiac arrhythmia w/ astemizole, cisapride, dofetilide, halofantrine, mizolastine, pimozide, quinidine, sertindole, terfenadine. May increase exposure to ergot alkaloids leading to ergotism. May increase the risk of rhabdomyolysis w/ HMG-CoA reductase inhibitors (e.g. simvastatin and lovastatin). May increase the effect of triazolam and oral midazolam.
Pregnancy Category: C Lactation: not known whether distributed into milk; use caution
Topical/Cutaneous Adult: Tinea cruris, corporis & cutaneous canidiasis: Apply to affected area BID for 2 weeks Tinea versicolor: Apply once daily to affected area for 2 weeks Tinea pedis: Apply BID to affected area for 4 weeks
Tinea <2 years: Safety and efficacy not established >2 years: Apply BID for up to 1 month
N/A
N/A
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.